BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 15, 2001
View Archived Issues
NIH technology available for licensing: antiprogestins with partial agonist activity
Read More
Alizyme: clinical and preclinical development program update
Read More
Update of Pozen's clinical drug candidates for migraine
Read More
ProstaRex shows broad T-cell response in preclinical prostate cancer studies
Read More
AeroGen reports product update
Read More
Boehringer Ingelheim prepares large international study for prevention of cardiovascular disease
Read More
OSI begins first in series of OSI-774 trials in combination with anticancer agents
Read More
Microsphere formulation of KNI-272 tested in HIV-infected patients
Read More
Alliance plans to continue development of Oxygent
Read More
Cumulative neuromuscular toxicity is dose-limiting for LU-79553
Read More
Positive results reported from phase III trial of Novavax's Estrasorb; NDA in preparation
Read More
Millennium gains rights to PDL's antibody humanization patents
Read More
Controlled trial examines efficacy of embryonic dopamine neuron transplantation in PD
Read More
Nastech's nasal triptan enters phase I for migraine pain
Read More
Gastrointestinal and colonic prokinetic effects of prucalopride confirmed in constipated patients
Read More
Morphochem/Sosei collaboration will optimize anticancer telomerase inhibitor
Read More
Tibotec and Virco merger complete
Read More
Company Profile: Speedel
Read More
SB-273005, an orally active vitronectin receptor antagonist with disease-modifying properties
Read More
Shire seeks E.U. approval of Foznol
Read More
New doses of Kadian approved in U.S.
Read More
Patient enrollment complete in pivotal phase III trial of Xcytrin
Read More
Small-molecule inhibitors of cell adhesion in the Boehringer Ingelheim pipeline
Read More
Oral prodrugs of immunosuppressive/antiallergic compounds prepared at Shionogi
Read More
Shionogi identifies new series inhibiting sPLA2
Read More
AHP scientists claim new bicyclic vitronectin antagonists and use in osteoporosis
Read More
GlycoTech presents new sialyl-Lewis(a) and sialyl-Lewis(x) analogues
Read More